Blueprint Medicines Trading Volume Drops 4166% to 206th Position Despite Revenue Growth

On June 17, 2025, Blueprint Medicines (BPMC) saw a significant decline in trading volume, with a total of $38.5 million in shares traded, marking a 41.66% decrease from the previous day. This placed BPMC at the 206th position in terms of trading volume for the day. The stock closed flat, indicating a stable performance despite the drop in trading activity.

Wells Fargo & Company has adjusted its rating for Blueprint Medicines (BPMC) from Overweight to Equal Weight, accompanied by a revised price target of $129, down from the previous $143. This change is primarily due to the anticipated acquisition by Sanofi, which has influenced Wells Fargo's reassessment of BPMC's market position.

Blueprint Medicines reported a 61% year-over-year growth in AYVAKIT revenue, reaching $149.4 million globally, with $129.4 million from the US and $20 million from international markets. The company has raised its revenue guidance for the year to $700 million to $720 million, reflecting confidence in sustained growth. Additionally, BPMC's strong cash position of $900 million supports its ability to invest in innovation and growth.

Despite these positive developments, BPMC faces typical Q1 financial challenges, including insurance dynamics and fewer ordering days, which impact quarterly performance. International revenue growth was flat quarter-over-quarter, with only Germany having ISM reimbursement, limiting broader international expansion. The company also anticipates modest increases in R&D and SG&A expenses, which could affect short-term profitability.